Key Developments: Prestige Brands Holdings Inc (PBH.N)
34.66USD
1 Aug 2013
$0.75 (+2.21%)
$33.91
$34.02
$35.56
$33.81
78,826
97,962
$35.98
$15.05
Latest Key Developments (Source: Significant Developments)
Prestige Brands Holdings Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates
Prestige Brands Holdings Inc anticipated revenue for fiscal 2014, to be in the range of $638-$643 million, which includes approximately $13 million in revenue from Care (AUD15 million). According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $635 million for fiscal 2014. Full Article
Prestige Brands Holdings Inc Acquires Care Pharmaceuticals
Prestige Brands Holdings Inc announced its acquisition of Care Pharmaceuticals Pty Ltd. (Care) of Bondi Junction, New South Wales, Australia, a privately-held marketer and distributor of over-the-counter (OTC) healthcare brands for children and adults. The acquisition is effective July 1, 2013. Prestige funded the acquisition with a combination of its existing credit facility and cash on the balance sheet. Financial terms of the acquisition have not been disclosed. Sawaya Segalas, Inc. LLC acted as exclusive financial advisor to Prestige Brands on this transaction. Full Article
Prestige Brands Holdings Inc Raises FY 2013 EPS Guidance
Prestige Brands Holdings Inc raised fiscal 2013 adjusted earnings per share (EPS) guidance to $1.45-$1.48 per share from $1.37-$1.42. Full Article
Prestige Brands Holdings Inc Raises FY 2013 EPS Guidance
Prestige Brands Holdings Inc announced that with strong first half performance, strategy in place, and a well-positioned portfolio of consumer brands, it is confident in raising earnings guidance for fiscal 2013 from $1.22-$1.32 to $1.37-$1.42 per share. Full Article
Prestige Brands Holdings Inc Reaffirms FY 2013 EPS Guidance
Prestige Brands Holdings Inc announced that it is confident in guidance previously provided for fiscal 2013, anticipating diluted adjusted earnings per share to be in the range of $1.22 to $1.32. According to I/B/E/S Estimates, were expecting the Company to report EPS of $1.27 for fiscal 2013. Full Article
Genomma Lab Internacional SAB de CV Decides Not To Proceed With Acquisition Of Total Stake In Prestige Brands Holdings Inc
Genomma Lab Internacional SAB de announced that on May 3, 2012 it decided not to proceed with the acquisition of the total amount of the outstanding shares of Prestige Brands Holdings Inc, at a price of USD 16.60 per share due to disagreement between the parties on the offer price. Full Article
Genomma Lab Internacional SAB de CV Obtains Loan from Bank of America Merrill Lynch and Jefferies Finance LLC To Acquire 100% Stake in Prestige Brands Holdings Inc
Genomma Lab Internacional SAB de CV announced that it has obtained a loan from Bank of America Merrill Lynch and Jefferies Finance LLC to acquire a 100% stake in Prestige Brands Holdings Inc at a value of USD 16.60 per share. Other details were not disclosed. Full Article
Prestige Brands Holdings, Inc. Completes Purchase Of Debrox And Gly-Oxide From GlaxoSmithKline
Prestige Brands Holdings, Inc. announced that it has completed the purchase of the two remaining brands of the seventeen brands it agreed to acquire from GlaxoSmithKline (GSK) on December 20, 2011.The purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction. The purchase of fifteen of the seventeen brands Prestige agreed to acquire was completed on January 31, 2012 for $615 million. The subsequent purchase of the remaining two brands finalizes the transaction, which called for Prestige to pay a total of $660 million in cash plus a customary post-closing inventory adjustment under the original terms of the agreements. Sawaya Segalas & Company, Inc. LLC acted as exclusive financial advisor to Prestige Brands in these transactions. Full Article
Prestige Brands Holdings, Inc. Issues Q4 2012 Guidance Above Analysts' Estimates; Issues FY 2013 EPS Guidance Above Analysts' Estimates
Prestige Brands Holdings, Inc. announced that for the fourth quarter of 2012, it expects to report net revenues of approximately $133.0 million, adjusted net income of approximately $11.8 million, or approximately $0.23 per diluted share, up substantially from GAAP net income of $6.4 million, or $0.13 per diluted share, in the year-ago quarter. For fiscal 2013, it expects to report diluted adjusted earnings per share (EPS) in the range of $1.22 to $1.32. This estimate also excludes costs related to the TSA and integration, legal and professional expenditures, as well as other acquisition-related costs. According to I/B/E/S Estimates, were expecting the Company to report EPS of $0.22 and revenue of $126 million for fourth quarter of 2012 and EPS of $1.21 for fiscal 2013. Full Article
Prestige Brands Holdings Inc Rejects Unsolicited Proposal From Genomma Lab
Prestige Brands Holdings, Inc. announced that its Board of Directors has unanimously rejected Genomma Lab Internacional, S.A.B. de C.V.’s unsolicited, conditional proposal to acquire the Company for $16.60 per share, as set forth in Genomma Lab’s February 21, 2012 public letter. The Prestige Brands Board of Directors has reviewed the Genomma Lab letter with the assistance of its financial and legal advisors and, after thorough consideration in accordance with its fiduciary duties, has determined that the proposed price is inadequate and the proposal is not in the best interests of Prestige Brands and its stockholders. Full Article

Earnings vs.
Estimates